Pacira BioSciences/PCRX

$26.53

-1.11%
-
1D1W1MYTD1YMAX

About Pacira BioSciences

Pacira BioSciences, Inc. is a holding company for Pacira Pharmaceuticals, Inc. The Company's non-opioid treatments include EXPAREL (bupivacaine liposome injectable suspension), which is a long-acting, local analgesic for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), which is an extended-release, intra-articular (IA), corticosteroid injection indicated for OA knee pain, and Iovera, which is a novel handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. EXPAREL is used across multiple orthopedic procedures, including joint reconstruction, shoulder, spine, extremity procedures, and hip fractures. It is developing interventions to address debilitating conditions involving the sympathetic nervous system, such as cardiac electrical storm, chronic pain. Its clinical development programs include PCRX-201, and pMVL-Based Clinical Program.

Ticker

PCRX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Frank Lee

Employees

711

Headquarters

Tampa, United States

PCRX Metrics

BasicAdvanced
$1.25B
Market cap
39.52
P/E ratio
$0.68
EPS
0.76
Beta
-
Dividend rate
$1.25B
0.7646
$48.60
$25.93
474.77K
5.237
4.165
59.048
60.041
14.562
9.85%
2.58%
5.1%
2.79%
39.522
1.848
1.433
5.579
8.944
1.22%
133.69%
16.25%
-35.68%

What the Analysts think about PCRX

Analyst Ratings

Majority rating from 11 analysts.
Buy

Price Targets

Average projection from 10 analysts.
74.9% upside
High $57.00
Low $36.00
$26.53
Current price
$46.40
Average price target

PCRX Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
13.68% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$181.2M
10.56%
Net income
$24.8M
129.63%
Profit margin
13.68%
107.9%

PCRX Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 0.75%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
$0.53
$0.78
$0.72
$0.89
-
Expected
$0.62
$0.76
$0.78
$0.88
$0.63
Surprise
-14.1%
2.9%
-8.16%
0.75%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Pacira BioSciences stock?

Pacira BioSciences (PCRX) has a market cap of $1.25B as of April 16, 2024.

What is the P/E ratio for Pacira BioSciences stock?

The price to earnings (P/E) ratio for Pacira BioSciences (PCRX) stock is 39.52 as of April 16, 2024.

Does Pacira BioSciences stock pay dividends?

No, Pacira BioSciences (PCRX) stock does not pay dividends to its shareholders as of April 16, 2024.

When is the next Pacira BioSciences dividend payment date?

Pacira BioSciences (PCRX) stock does not pay dividends to its shareholders.

What is the beta indicator for Pacira BioSciences?

Pacira BioSciences (PCRX) has a beta rating of 0.76. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Pacira BioSciences stock price target?

The target price for Pacira BioSciences (PCRX) stock is $46.4, which is 74.9% above the current price of $26.53. This is an average based on projections from 10 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Pacira BioSciences stock

Buy or sell Pacira BioSciences stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing